Kromek listed on the AIM market in October, 2013 and is a UK company pioneering digital colour imaging for x-rays using cadmium zinc telluride crystals.
Interim Results - H1 24: profitability up, costs reduced
Results highlight the emergence of demand for Kromek’s Advanced Imaging and CBRN detection,...
Read moreBio-detection becomes a commercial reality
Recent new contracts show that Kromek’s investment in bio-hazard detection technology is becoming a...
Read moreEncouraging H2 supports a positive outlook
For the year to 30 April 2023 Kromek reported revenue of £17.3m, +44%YoY, and an EBITDA (adj.) loss...
Read moreFunding the opportunity in medical imaging
On 18 April Kromek announced a major seven-year agreement with a Tier 1 OEM to develop and...
Read moreMajor medical imaging agreement, trading update
Kromek Group has announced a major, seven-year agreement to supply its CZT-based detectors to a...
Read moreTimely reminders of an unsafe world
As the acronym suggests, Kromek’s technology in the CBRN segment detects a wide range of threats,...
Read moreH1 23 results: revenue +44%YoY
For the six months to 31 October 2022 Kromek reported revenue of £6.8m, +44.1% YoY, gross profit of...
Read more£5m biological threat-detection contract award
Kromek Group has announced the award of a three-year UK Government department biological...
Read moreFY22 results and a highly visible outlook
For the year to 30 April 2022 Kromek reported results in line with the Trading Update of 16 May:...
Read moreTrading update: FY23 targets remain on course
In a Trading Update for the year to 30 April 2022 Kromek reports that it expects FY22 revenue of...
Read moreEstablished leader in detection solutions
Kromek delivered a sound, well-managed, H1 performance given industry-wide supply chain and...
Read more$17m contract win for production inspection systems
Kromek announced today that it had been awarded a 7 year $17m contract with a large US OEM to...
Read more- Prev
- 1 of 3 pages
- Next